AMM Safety First Trust Principal-Protected Trust Certificates Linked TO The S&P 500 Index

AMS Health Sciences, Inc (AMEX:AMM) announced today the settlement of Randal Potter et al v. Advantage Marketing Systems, Inc., the final lawsuit pending against the Company involving its products containing ephedra. In Potter, the plaintiff alleged that the ingestion of ephedra included in the Company's AM-300 product resulted in the death of Pamela Sue Potter. The exact settlement terms are confidential. "This is a tremendous relief for the Company and its stockholders," said Dr. Jerry W. Grizzle, President and CEO of AMS. "We have worked diligently with all parties involved to bring this to an equitable and satisfactory closing. This settlement releases the Company from all liabilities, current or future, related to the claims alleged in the original lawsuit." This settlement resolves the last piece of litigation dealing with the sale of AM-300, an ephedra-based product. The Food and Drug Administration (FDA) banned the sale of ephedra in April 2004. In compliance with the FDA ruling, the Company terminated all sales of AM-300. The Company is not aware of any other claims that might result in future litigation regarding the ingestion of ephedra through the Company's products. AMS Health Sciences, Inc., sells more than 60 natural nutritional supplements, weight management products, and natural skincare products through independent distributors across the United States and Canada. More information about the Company is available at http://www.amsonline.com.